Baidu
map

Nat Genet:携带BRCA2突变的吸烟者更易患上肺癌

2014-06-09 佚名 生物通

最近的一项新研究证实,BRCA2和CHEK2基因变异,特别是突变型BRCA2,可以大大增加个人患肺癌的风险。如果吸烟者携带BRCA2变异,其患肺癌的风险可能翻倍。由伦敦癌症研究所、法国国际癌症研究机构、美国国家癌症研究所和美国达特茅斯学院等研究结构组成的国际合作小组,利用来自1000个肺癌遗传学研究基因组项目的综合结果,完成了这一研究,相关结果发表在2014年6月1日的《自然遗传学》(Natu

最近的一项新研究证实,BRCA2和CHEK2基因变异,特别是突变型BRCA2,可以大大增加个人患肺癌的风险。如果吸烟者携带BRCA2变异,其患肺癌的风险可能翻倍。

由伦敦癌症研究所、法国国际癌症研究机构、美国国家癌症研究所和美国达特茅斯学院等研究结构组成的国际合作小组,利用来自1000个肺癌遗传学研究基因组项目的综合结果,完成了这一研究,相关结果发表在2014年6月1日的《自然遗传学》(Nature Genetics)。

研究扫描了1.1万多欧洲血统人口的基因组,寻找非小细胞癌(肺癌的常见形式)相关的常见变异。分析表明,BRCA2和CHEK2基因变异,可以大大增加肺癌的个人发展风险。如果吸烟者携带BRCA2变异,其罹患肺癌的风险可能翻倍。此外,在这些欧洲血统人口中,TP63基因(以前认为只与在亚洲人肺癌风险相关)与腺癌(一种非小细胞肺癌)的风险有关。

本研究利用来自于德克萨斯大学M.D.安德森癌症中心、英国癌症研究院、美国国家癌症研究所和国际癌症研究机构的四项全基因组关联(GWA)研究。科学家们使用基因填补(imputation)计算——一种基于观察对象已有基因型,对未进行基因分型的位点之等位基因进行预测的方法。

本文资深作者、达特茅斯基因组医学中心主任Chris Amos博士称:“这种计算方法,使我们通过全基因组关联研究,发现了迄今最强的癌症关联,并确定了一部分人,他们特别容易受到吸烟相关的伤害。”

BRCA2基因编码一个非常大的蛋白质,主要功能是协调许多不同DNA修复相关基因的活动。由于环境毒素(如包含在烟草烟雾中的毒素),细胞会积聚DNA损伤。BRCA2突变可能会影响细胞响应DNA损伤的能力,增加细胞变成癌症的机会。

以前的研究并没有发现BRCA2和肺癌之间的关系。在这项研究中,所有四个GWA数据集分析均表明,BRCA2基因(rs11571833)和非小细胞肺癌(特别是鳞状细胞癌)之间存在显著的关联。此外,结果证实了以前的研究,将CHEK2 (rs17879961)与鳞状细胞癌联系在一起。在欧洲血统人口中发现的TP63 (rs13314271)变异,有力证明了其与腺癌之间的关联。

该研究负责人、英国癌症研究所分子和群体遗传学教授Richard Houlston称:“我们的研究表明,在吸烟的情况下,BRCA2和CHEK2两个基因的突变,对肺癌风险具有很大的影响。特别是突变型BRCA2,可能增加1.8倍的风险。一般吸烟者患肺癌的可能性接近于15%,远高于非吸烟者。我们的研究结果表明,一些携带BRCA2突变的吸烟者,具有患上肺癌的巨大风险(25%)。每年,肺癌夺去全世界超过100万人的生命,是迄今为止最大的癌症杀手。我们知道,对于降低死亡率而言,我们唯一可以做的就是,说服人们不要吸烟,我们的新研究清楚的表明,对于具有潜在遗传风险的人来说,戒烟尤为重要。”

这项研究结果,可能会影响肺癌患者的筛选和治疗。携带基因突变的吸烟者,可能是低剂量CT扫描筛查肺癌的候选人。由于携带BRCA1或BRCA2胚系突变的人,对一种特定的化疗方法(称为PARP抑制)有反应,因此,比其他肺癌病例相比,携带这个BRCA2突变的肺癌患者,可能同样会积极地响应PARP抑制疗法。

原始出处:

Wang Y1, McKay JD2, Rafnar T3, Wang Z4, Timofeeva MN5, Broderick P6, Zong X7, Laplana M8, Wei Y9, Han Y10, Lloyd A6, Delahaye-Sourdeix M5, Chubb D6, Gaborieau V5, Wheeler W11, Chatterjee N4, Thorleifsson G3, Sulem P3, Liu G12, Kaaks R13, Henrion M6, Kinnersley B6, Vallée M5, LeCalvez-Kelm F5, Stevens VL14, Gapstur SM14, Chen WV15, Zaridze D16, Szeszenia-Dabrowska N17, Lissowska J18, Rudnai P19, Fabianova E20, Mates D21, Bencko V22, Foretova L23, Janout V24, Krokan HE25, Gabrielsen ME25, Skorpen F26, Vatten L27, Njølstad I28, Chen C29, Goodman G29, Benhamou S30, Vooder T31, Välk K32, Nelis M33, Metspalu A34, Lener M35, Lubiński J35, Johansson M5, Vineis P36, Agudo A37, Clavel-Chapelon F38, Bueno-de-Mesquita HB39, Trichopoulos D40, Khaw KT41, Johansson M42, Weiderpass E43, Tjønneland A44, Riboli E45, Lathrop M46, Scelo G5, Albanes D4, Caporaso NE4, Ye Y47, Gu J47, Wu X47, Spitz MR48, Dienemann H49, Rosenberger A50, Su L9, Matakidou A51, Eisen T52, Stefansson K3, Risch A53, Chanock SJ4, Christiani DC9, Hung RJ7, Brennan P5, Landi MT54, Houlston RS55, Amos CI56.Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer.Nat Genet. 2014 Jun 1. doi: 10.1038/ng.3002. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048592, encodeId=00d4204859271, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Jan 25 21:17:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685945, encodeId=dc2e168594580, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 14 16:17:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715647, encodeId=e2581e1564719, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Tue Aug 12 13:17:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733690, encodeId=a6321e33690b0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 15 22:17:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880099, encodeId=d71c18800993b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 04 05:17:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593982, encodeId=1a5b1593982fa, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602834, encodeId=663916028341d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605082, encodeId=7f031605082c4, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
    2015-01-25 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048592, encodeId=00d4204859271, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Jan 25 21:17:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685945, encodeId=dc2e168594580, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 14 16:17:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715647, encodeId=e2581e1564719, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Tue Aug 12 13:17:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733690, encodeId=a6321e33690b0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 15 22:17:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880099, encodeId=d71c18800993b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 04 05:17:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593982, encodeId=1a5b1593982fa, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602834, encodeId=663916028341d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605082, encodeId=7f031605082c4, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048592, encodeId=00d4204859271, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Jan 25 21:17:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685945, encodeId=dc2e168594580, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 14 16:17:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715647, encodeId=e2581e1564719, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Tue Aug 12 13:17:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733690, encodeId=a6321e33690b0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 15 22:17:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880099, encodeId=d71c18800993b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 04 05:17:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593982, encodeId=1a5b1593982fa, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602834, encodeId=663916028341d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605082, encodeId=7f031605082c4, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
    2014-08-12 yige2014
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048592, encodeId=00d4204859271, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Jan 25 21:17:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685945, encodeId=dc2e168594580, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 14 16:17:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715647, encodeId=e2581e1564719, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Tue Aug 12 13:17:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733690, encodeId=a6321e33690b0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 15 22:17:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880099, encodeId=d71c18800993b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 04 05:17:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593982, encodeId=1a5b1593982fa, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602834, encodeId=663916028341d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605082, encodeId=7f031605082c4, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
    2014-10-15 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=2048592, encodeId=00d4204859271, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Jan 25 21:17:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685945, encodeId=dc2e168594580, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 14 16:17:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715647, encodeId=e2581e1564719, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Tue Aug 12 13:17:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733690, encodeId=a6321e33690b0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 15 22:17:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880099, encodeId=d71c18800993b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 04 05:17:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593982, encodeId=1a5b1593982fa, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602834, encodeId=663916028341d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605082, encodeId=7f031605082c4, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
    2015-01-04 liye789132251
  6. [GetPortalCommentsPageByObjectIdResponse(id=2048592, encodeId=00d4204859271, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Jan 25 21:17:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685945, encodeId=dc2e168594580, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 14 16:17:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715647, encodeId=e2581e1564719, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Tue Aug 12 13:17:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733690, encodeId=a6321e33690b0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 15 22:17:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880099, encodeId=d71c18800993b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 04 05:17:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593982, encodeId=1a5b1593982fa, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602834, encodeId=663916028341d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605082, encodeId=7f031605082c4, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2048592, encodeId=00d4204859271, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Jan 25 21:17:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685945, encodeId=dc2e168594580, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 14 16:17:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715647, encodeId=e2581e1564719, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Tue Aug 12 13:17:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733690, encodeId=a6321e33690b0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 15 22:17:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880099, encodeId=d71c18800993b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 04 05:17:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593982, encodeId=1a5b1593982fa, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602834, encodeId=663916028341d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605082, encodeId=7f031605082c4, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
    2014-06-11 TZF0810
  8. [GetPortalCommentsPageByObjectIdResponse(id=2048592, encodeId=00d4204859271, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Jan 25 21:17:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685945, encodeId=dc2e168594580, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 14 16:17:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715647, encodeId=e2581e1564719, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Tue Aug 12 13:17:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733690, encodeId=a6321e33690b0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 15 22:17:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880099, encodeId=d71c18800993b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 04 05:17:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593982, encodeId=1a5b1593982fa, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602834, encodeId=663916028341d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605082, encodeId=7f031605082c4, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Wed Jun 11 00:17:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]

相关资讯

ASCO 2014肺癌专场:中国3项EGFR靶向辅助治疗试验

第50届美国临床肿瘤学会年会(ASCO2014)正在美国芝加哥召开。美国芝加哥时间5月30日,在ASCO">ASCO年会教育专场“肺癌50年:非小细胞肺癌(NSCLC)目前治疗——辅助治疗、放化疗和系统治疗”上,来自美国斯坦福大学斯坦福癌症研究所的Wakelee教授,围绕50年来NSCLC辅助治疗情况进行了介绍。其中,在EGFR靶向辅助治疗饰演的介绍中,特别提及了来自中国的3项研究(NCT0

ASCO 2014:全国低剂量CT(LDCT)肺癌筛查研究

摘要号:#6501题目:医疗保险Medicare项目中的低剂量CT(LDCT)肺癌筛查:反映出的临床、资源和预算影响背景:基于国家肺癌筛查试验(NLST)中获得的证据,美国预防服务任务组(USPSTF)近期推荐对目前吸烟者既往吸烟30包/年或过去15年内戒烟的55-80岁患者,每年进行LDCT肺癌筛查。根据平价医疗法案条款,Medicare将给付筛查费用。我们对该政策的临床、资源和预算影响做一调查

ASCO 2014:陆舜谈新EGFR抑制剂对NSCLC的疗效研究

新EGFR抑制剂AZD9291对难治性NSCLC显示出有前景的活性 题目:EGFR抑制剂耐药的非小细胞肺癌(NSCLC)患者中应用突变选择性EGFR抑制剂AZD9291的临床活性(Clinical activity of the mutant selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor resis

Nat Med:血液样本为跟踪肺癌提供新的方法

日前,来自英国曼彻斯特大学的研究人员示范了如何利用肺癌患者的血液样本来监视及预测他们对于治疗的反应,从而为个体化治疗这一疾病铺平了道路。这项刊登在《自然-医学》(Nature Medicine)杂志上的最新研究还为在实验室中展开新疗法测试及更好地了解肿瘤的耐药机制提供了一种方法。 小细胞肺癌(SCLC)是一种存活率较差的侵袭性癌症,迫切需要新的治疗方法。在许多情况下肿瘤不能施行手术,也难于获得活

ASCO 2014:遵循USPSTF指南筛查肺癌的利与弊

2013年12月发布的美国预防服务工作组(USPSTF)肺癌筛查指南推荐,年龄55-80岁且有吸烟30包-年史的当前吸烟者或已戒烟15年者每年接受一次小剂量CT筛查肺癌。即将在2014年ASCO大会上报告的一项研究旨在评估根据USPSTF指南进行肺癌筛查的临床获益和经济成本。研究结果显示,根据美国预防医学服务工作组(USPSTF)指南进行的肺癌筛查会增加癌症检出数量,特别是早期癌症,但是也会增加医

Ib期肺癌,如何合理开展辅助治疗?

我国早期肺癌治疗的主要问题就是“过度治疗”:以前认为辅助化疗对Ib期非小细胞肺癌(NSCLC)有效,但大量研究证据表明这样治疗的益处并不大,从长远看化疗药物甚至会带来损伤;2008年发表的一项评价Ⅰ期肺癌辅助治疗疗效的研究对患者追踪了7年,发现死亡的患者大多不是死于癌症,而是化疗的毒副作用。但是,很多医生仍对ⅠB期患者进行辅助化疗,他们觉得把能用的治疗措施都用足了,患者出问题就不是他们的责任了

Baidu
map
Baidu
map
Baidu
map